Anne Li Feburary 11th, 2016
Patients with cancer that has spread to their bones can receive less-frequent treatments to prevent fractures and other bone-related complications without sacrificing efficacy of the treatment, results from a large clinical trial show. In the phase III clinical trial, patients with bone metastases who received infusions of zoledronic acid every 12 weeks did not have more bone fractures or related problems than patients who received the drug every 4 weeks, the schedule that is commonly used in everyday patient care. Although the trial investigators did not see a reduction in side effects with the less frequent infusions, patients receiving the drug every 12 weeks were almost twice as likely to receive their treatments as scheduled.
See original article at: https://www.cancer.gov/news-events/cancer-currents-blog/2017/zoledronic-acid-bone-metastasis